Multidrug-resistant Pseudomonas aeruginosa bloodstream infections: risk factors and mortality.
about
The Effect of Infection Control Nurses on the Occurrence of Pseudomonas aeruginosa Healthcare-Acquired Infection and Multidrug-Resistant Strains in Critically-Ill ChildrenThe Use of Bloodstream Infection Mortality to Measure the Impact of Antimicrobial Stewardship Interventions: Assessing the EvidenceBloodstream infections in patients with hematological malignancies: which is more fatal - cancer or resistant pathogens?A prediction tool for nosocomial multi-drug Resistant Gram-Negative Bacilli infections in critically ill patients - prospective observational study.Clinical and treatment-related risk factors for nosocomial colonisation with extensively drug-resistant Pseudomonas aeruginosa in a haematological patient population: a matched case control study.Effect of metallo-β-lactamase production and multidrug resistance on clinical outcomes in patients with Pseudomonas aeruginosa bloodstream infection: a retrospective cohort study.Pseudomonas aeruginosa: resistance to the maxEpidemiological interpretation of studies examining the effect of antibiotic usage on resistanceA cohort study of bacteremic pneumonia: The importance of antibiotic resistance and appropriate initial therapy?In vitro activity of ceftolozane-tazobactam against Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals in the CANWARD study, 2007 to 2012.Pseudomonas aeruginosa treatment and transmission reduction.A systematic review and meta-analyses show that carbapenem use and medical devices are the leading risk factors for carbapenem-resistant Pseudomonas aeruginosa.Stress responses as determinants of antimicrobial resistance in Pseudomonas aeruginosa: multidrug efflux and more.IRF3 Inhibits Neutrophil Recruitment in Mice Infected with Pseudomonas aeruginosa.Tobramycin inhalation powder for the treatment of pulmonary Pseudomonas aeruginosa infection in patients with cystic fibrosis: a review based on clinical evidence.Rapid and Consistent Evolution of Colistin Resistance in Extensively Drug-Resistant Pseudomonas aeruginosa during Morbidostat Culture.Patient specific risk stratification for antimicrobial resistance and possible treatment strategies in gram-negative bacterial infections.Analysis of a long-term outbreak of XDR Pseudomonas aeruginosa: a molecular epidemiological study.Multidrug-resistant Proteus mirabilis bloodstream infections: risk factors and outcomes.Clinical outcomes of Pseudomonas aeruginosa pneumonia in intensive care unit patients.Intracellular Synthesis of Gold Nanoparticles Using an Ectomycorrhizal Strain EM-1083 of Laccaria fraterna and Its Nanoanti-quorum Sensing Potential Against Pseudomonas aeruginosa.Risk Factors and Outcomes for Ineffective Empiric Treatment of Sepsis Caused by Gram-Negative Pathogens: Stratification by Onset of Infection.Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: Clinical Effectiveness and Evolution of Resistance.Framework for controlling infection through isolation precautions in Japan.Risk factors for hospitalized patients with resistant or multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis.
P2860
Q28551240-7C6FC701-2871-4CA9-85AA-6BAF22323F98Q33564316-6EB64B9F-A21C-4B7C-93CC-4BB1EA5D64F2Q34229622-CBD50905-14AC-40EA-825A-062F6DEA8B25Q34611874-9B087A03-1A17-4C59-B938-39AF3DD53240Q34700642-F8876D40-F50B-4850-8F9C-CD207E01A9DEQ35029541-8245849A-E9FE-4FEA-8B53-BD0B399C77D7Q35084559-B6FFC803-4914-4925-9D49-D39A66FE73EDQ36757737-20A177C1-51FD-4E7B-B663-54401EFFB9C1Q37226357-7DED8747-EDDD-4473-818F-8D99F24AD6DBQ37263317-E2178B5C-F8E1-4DF7-8E9A-D4A887409347Q38131538-923C6EE7-866F-495D-8BE2-C581AACCEA23Q38189330-5D0371B7-FCB7-4B9D-A6D9-F09576F8137CQ38267242-DC0105C5-2ED6-4D28-92E2-2E4F53762655Q38970650-9D6CE0EB-0355-4938-A530-5ED812380DE9Q39282311-5A702646-3B59-4F8A-99B9-F323BE8DBB13Q40166144-B5F4E4C4-D573-4DC3-AA7E-86F958DD1D3CQ40494723-BA384099-23B1-4442-A69E-9372E2A1EEA0Q41547433-7E746308-6F50-4BE5-B2DB-DB6001E53837Q41821207-9BC30050-2869-4317-8A48-5CC2C2D76DBAQ42276769-78BD7EF8-BE00-4C82-B0C8-C8490DC16053Q47449825-910EBFBD-3A6C-4901-B7E6-ECC97D0C1ACFQ47647007-18EE6A44-B335-43BD-9D8E-9E67A452A06EQ47748447-5A5961B0-B105-4EAF-80E0-B11D2A5A5A47Q50677348-E251B493-8C97-4908-8BBB-92ED50F80799Q55649599-6784DC82-B371-446D-93A4-176E85CED0CE
P2860
Multidrug-resistant Pseudomonas aeruginosa bloodstream infections: risk factors and mortality.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Multidrug-resistant Pseudomona ...... factors and mortality.
@en
Multidrug-resistant Pseudomona ...... factors and mortality.
@nl
type
label
Multidrug-resistant Pseudomona ...... factors and mortality.
@en
Multidrug-resistant Pseudomona ...... factors and mortality.
@nl
prefLabel
Multidrug-resistant Pseudomona ...... factors and mortality.
@en
Multidrug-resistant Pseudomona ...... factors and mortality.
@nl
P2093
P2860
P1476
Multidrug-resistant Pseudomona ...... factors and mortality.
@en
P2093
A Parisini
C Bernardini
E M Trecarichi
G De Pascale
M Bassetti
M P Molinari
M Tumbarello
P2860
P304
P356
10.1017/S0950268810003055
P577
2011-11-01T00:00:00Z